Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.
[hodgkin lymphoma, classical]
Twelve
consecutive
patients
with
classical
Hodgkin
lymphoma
(
HL
)
involving
diaphragmatic
or
subdiaphragmatic
regions
were
treated
on
an
institutional
review
board-approved
outcomes
tracking
protocol
.
All
patients
underwent
treatment
with
proton
therapy
following
chemotherapy
and
had
comparative
three
-dimensional
conformal
photon
radiotherapy
(
3
DCRT
)
and
intensity-modulated
radiotherapy
(
IMRT
)
plans
to
evaluate
differences
in
dose
to
organs
at
risk
(
OARs
)
.
Among
the
cohort
,
stomach
doses
with
3
DCRT
,
IMRT
and
proton
therapy
were
21
Gy
(
median
)
,
14
Gy
and
6
Gy
,
respectively
.
Median
dose
reductions
with
proton
therapy
compared
with
3
DCRT
and
IMRT
were
13
Gy
(
p
=
0
.
0022
)
and
8
Gy
(
p
=
0
.
0022
)
for
the
stomach
.
Additionally
,
there
was
significant
dose
reduction
using
proton
therapy
for
the
liver
,
pancreas
,
bowel
,
left
kidney
and
right
kidney
.
Proton
therapy
reduces
the
dose
to
the
stomach
,
liver
,
pancreas
,
small
bowel
and
kidneys
compared
with
3
DCRT
or
IMRT
in
patients
with
HL
requiring
abdominal
radiotherapy
.
These
dose
reductions
are
expected
to
translate
into
lower
risks
of
secondary
cancers
and
other
late
toxicities
in
survivors
of
HL
.
Diseases
Validation
Diseases presenting
"hodgkin lymphoma"
symptom
esophageal adenocarcinoma
hodgkin lymphoma, classical
monosomy 21
primary effusion lymphoma
severe combined immunodeficiency
systemic capillary leak syndrome
waldenström macroglobulinemia
This symptom has already been validated